Form 4: Alnylam Director Bonney Executes Stock Option, Sells Shares

Michael W. Bonney, a director at Alnylam Pharmaceuticals, exercised stock options and sold shares under a prearranged trading plan.

Summary

• On August 18, 2025, Michael W. Bonney exercised stock options to acquire 11,250 shares of Alnylam Pharmaceuticals common stock at a price of $70.20 per share.
• On the same day, Bonney sold 11,250 shares of common stock at $450 per share.
• Following these transactions, Bonney directly owns 16,804 shares of Alnylam common stock.
• Bonney also indirectly owns 4,000 shares through the Michael W. Bonney Revocable Trust.

Sentiment

Score: 5

Explanation: Neutral. The filing simply reports transactions. The exercise of options is a positive, but the sale is a negative. The 10b5-1 plan makes it neutral overall.

Positives

• The exercise of stock options indicates Bonney's confidence in Alnylam's future prospects.
• The sale of shares at $450 realizes a significant gain compared to the option exercise price of $70.20.

Negatives

• The sale of 11,250 shares may be perceived negatively by some investors, although it was conducted under a prearranged trading plan.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives and directors of publicly traded companies. These transactions are subject to regulatory scrutiny to prevent insider trading.

Stakeholder Impact

• Shareholders: The transactions may have a minor impact on the stock price, but the prearranged trading plan mitigates concerns about insider trading.
• Employees: No direct impact.

Key Dates

Recommendation

The transactions are part of a pre-arranged trading plan, suggesting they are not based on new material non-public information. Therefore, a hold recommendation is appropriate.

Keywords

Alnylam Pharmaceuticals, Michael W. Bonney, stock options, Form 4, insider trading, Rule 10b5-1, ALNY